Aim: To compare efficacy and safety of strepfen (flurbiprofen) to those of oral paracetamol in acute infections of the upper respiratory tracts for relief of throat pain (TP).

Material And Methods: Of 60 patients 30 ones took strepfen, 30 controls took paracetamol. The intensity and dynamics of throat pain and pharyngeal discomfort were assessed by 10-point subjective visual-analog scale.

Results: Strepfen is similar by an analgetic effect to paracetamol. Strepfen acts rapidly (in 5-15 min) and its analgetic effect lasts about 3 hours. Paracetamol begins to relieve pain 30-45 min after its intake. The drug is well tolerated, serious side effects are absent.

Conclusion: Strepfen can be recommended for relief of throat pains and pharyngeal paresthesia in patients with acute and chronic pharyngeal pathology.

Download full-text PDF

Source

Publication Analysis

Top Keywords

relief throat
8
throat pain
8
paracetamol
5
strepfen
5
[results open
4
open prospective
4
prospective controlled
4
controlled randomized
4
randomized comparative
4
comparative trial
4

Similar Publications

Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses.

View Article and Find Full Text PDF

Somatic symptom disorder (SSD) is characterized by persistent physical symptoms that cause significant distress and functional impairment. Despite the widespread use of serotonin reuptake inhibitors (SRIs) in treating SSD, some patients experience insufficient response, necessitating alternative therapeutic approaches. We report two cases of SSD that demonstrated significant improvement with vortioxetine, a novel antidepressant with multimodal serotonergic receptor activity.

View Article and Find Full Text PDF

Acute Epstein-Barr Virus and SARS-CoV-2 Coinfection: A Case Report.

Curr Health Sci J

September 2024

Postgraduate Program in Dentistry, Universidade do Grande Rio (UNIGRANRIO), Rio de Janeiro, Brazil.

Article Synopsis
  • An 18-year-old female was misdiagnosed with bacterial tonsillitis and treated with antibiotics, but subsequent tests revealed she had a coinfection of Epstein-Barr Virus (EBV) and SARS-CoV-2 (COVID-19).
  • Symptoms included throat pain, cough, and enlarged lymph nodes, while tests indicated active EBV infection and confirmed COVID-19.
  • This case highlights the challenge of diagnosing coinfections and the critical role of proper lab testing to avoid incorrect treatments that could worsen the patient's health.
View Article and Find Full Text PDF

Use of a nasal obturator of computer-aided design in managing hereditary hemorrhagic telangiectasia.

J Prosthet Dent

November 2024

Consultant Maxillofacial Surgeon, The Department of Maxillofacial, The University Hospitals of Leicester, The Leicester Royal Infirmary, Leicester, United Kingdom.

This clinical report describes the nonsurgical treatment of a patient suffering from severe epistaxis associated with hereditary hemorrhagic telangiectasia (HHT). Unlike the permanent surgical closure of the nostrils, known as the Young procedure, this treatment option provides interim relief from nasal obstruction. It includes the use of cone beam computed tomography (CBCT) and computer-aided design (CAD) to create a patient-specific silicone nasal obturator without the need for an impression of the nasal cavity, thereby preventing irritation to the delicate nasal mucosa that could instigate epistaxis.

View Article and Find Full Text PDF

Background: Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.

Methods: This retrospective study evaluated 18 vaccinated outpatients (15 men; median age, 39.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!